Liles et al. demonstrated that the FXR agonist GS-9674 reduced serum transaminases, liver fibrosis, and steatosis in high-fat, cholesterol, and sugar diet-induced mouse NAFLD [106]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.